Your browser doesn't support javascript.
loading
Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy.
Penning-van Beest, Fernie J A; Bezemer, Irene D; Smits, Elisabeth; García Rodríguez, Luis A; Cea Soriano, Lucía; Lapi, Francesco; Simonetti, Monica; Asiimwe, Alex; Herings, Ron M C.
Afiliação
  • Penning-van Beest FJA; PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands. Electronic address: pharmo@pharmo.nl.
  • Bezemer ID; PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands.
  • Smits E; PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands.
  • García Rodríguez LA; Spanish Centre for Pharmacoepidemiologic Research, Madrid, Spain.
  • Cea Soriano L; Spanish Centre for Pharmacoepidemiologic Research, Madrid, Spain; Department of Public Health and Maternal Child Health, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain.
  • Lapi F; Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy.
  • Simonetti M; Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy.
  • Asiimwe A; Bayer AG, Berlin, Germany.
  • Herings RMC; PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Epidemiology and Biostatistics, Amsterdam, Netherlands.
Contraception ; 102(4): 243-245, 2020 10.
Article em En | MEDLINE | ID: mdl-32470466
ABSTRACT

OBJECTIVES:

To study the effect of risk minimization measures taken in 2013 for cyproterone acetate/ethinylestradiol (CPA/EE) on initiation, concomitant use of other hormonal contraceptives (HC) and potential indications. STUDY

DESIGN:

This retrospective study included data on CPA/EE use in 2011-2017 from the Netherlands, UK, and Italy.

RESULTS:

The initiation rate of CPA/EE decreased by 44%-91% between 2011 and 2017. Proportions with concomitant use of other HC (<3%) and approved indications did not change over time.

CONCLUSION:

Apart from a strong reduction in CPA/EE use following risk minimization measures, no major changes were observed regarding concomitant use of other HC or potential reasons for use.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acetato de Ciproterona / Acne Vulgar / Etinilestradiol Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acetato de Ciproterona / Acne Vulgar / Etinilestradiol Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2020 Tipo de documento: Article